$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017524 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$2.251M	$2.248M	$3.240M
YoY Change	-31.34%	-30.63%	6.24%
Cost Of Revenue	$606.3K	$690.7K	$1.905M
YoY Change	-71.23%	-63.74%	14.05%
Gross Profit	$1.645M	$1.557M	$1.336M
YoY Change	40.47%	16.57%	-3.21%
Gross Profit Margin	73.06%	69.27%	41.22%
Selling, General & Admin	$1.990M	$1.904M	$2.304M
YoY Change	-12.47%	-17.35%	13.51%
% of Gross Profit	121.01%	122.31%	172.51%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.820K	$2.821K	$3.970K
YoY Change	-85.7%	-28.94%
% of Gross Profit	0.17%	0.18%	0.3%
Operating Expenses	$1.990M	$1.904M	$2.304M
YoY Change	-12.47%	-17.35%	13.51%
Operating Profit	-$345.6K	-$347.4K	-$968.6K
YoY Change	-68.67%	-64.13%	49.01%
Interest Expense	$180.7K	$62.39K	-$1.360K
YoY Change	1874.16%	-4687.65%	-86.4%
% of Operating Profit
Other Income/Expense, Net	-$1.629M	$21.70K	$2.736K
YoY Change	17696.32%	693.02%
Pretax Income	-$1.975M	-$325.7K	-$965.8K
YoY Change	77.56%	-66.28%	48.59%
Income Tax
% Of Pretax Income
Net Earnings	-$1.975M	-$678.0K	-$965.8K
YoY Change	82.22%	-29.81%	48.24%
Net Earnings / Revenue	-87.73%	-30.16%	-29.81%
Basic Earnings Per Share	-$2.90	-$0.07	-$0.12
Diluted Earnings Per Share	-$2.90	-$0.06	-$117.4K
COMMON SHARES
Basic Shares Outstanding	10.21M shares	10.11M shares	8.178M shares
Diluted Shares Outstanding	681.2K shares	670.7K shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$745.6K	$1.194M	$1.871M
YoY Change	-22.52%	-36.17%	-64.09%
Cash & Equivalents	$745.6K	$1.200M	$1.871M
Short-Term Investments
Other Short-Term Assets	$388.8K	$357.9K	$411.6K
YoY Change	6.92%	-13.04%	-10.53%
Inventory	$161.3K	$126.3K	$274.0K
Prepaid Expenses	$388.8K	$357.9K
Receivables	$799.4K	$707.9K	$1.041M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.095M	$2.386M	$3.597M
YoY Change	-37.41%	-33.67%	-60.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.57K	$62.39K	$1.252M
YoY Change	-15.93%	-95.02%	140.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$49.03K	$49.03K	$49.03K
YoY Change	0.0%	0.0%	145.15%
Total Long-Term Assets	$1.650M	$1.652M	$2.243M
YoY Change	-29.04%	-26.37%	323.23%
TOTAL ASSETS
Total Short-Term Assets	$2.095M	$2.386M	$3.597M
Total Long-Term Assets	$1.650M	$1.652M	$2.243M
Total Assets	$3.745M	$4.038M	$5.840M
YoY Change	-33.98%	-30.86%	-39.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$863.6K	$515.8K	$908.5K
YoY Change	-27.75%	-43.23%	145.54%
Accrued Expenses	$376.3K	$303.2K	$520.2K
YoY Change	-13.94%	-41.71%	-18.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$166.7K
YoY Change	-100.0%	-100.0%	-27.53%
Total Short-Term Liabilities	$4.263M	$2.550M	$1.596M
YoY Change	67.41%	59.75%	28.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$333.3K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$776.6K	$832.5K	$1.023M
YoY Change	-21.42%	-18.62%	309.19%
Total Long-Term Liabilities	$776.6K	$832.5K	$1.356M
YoY Change	-21.42%	-38.62%	442.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.263M	$2.550M	$1.596M
Total Long-Term Liabilities	$776.6K	$832.5K	$1.356M
Total Liabilities	$5.040M	$3.383M	$2.970M
YoY Change	30.29%	13.89%	99.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.90M	-$19.90M
YoY Change	19.67%
Common Stock	$7.00	$100.00
YoY Change	-91.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.295M	$655.1K	$2.870M
YoY Change
Total Liabilities & Shareholders Equity	$3.745M	$4.038M	$5.840M
YoY Change	-33.98%	-30.86%	-39.73%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.975M	-$678.0K	-$965.8K
YoY Change	82.22%	-29.81%	48.24%
Depreciation, Depletion And Amortization	$2.820K	$2.821K	$3.970K
YoY Change	-85.7%	-28.94%
Cash From Operating Activities	$328.6K	-$931.5K	-$1.001M
YoY Change	-127.88%	-6.92%	40.95%
INVESTING ACTIVITIES
Capital Expenditures	$51.81K	$87.07K
YoY Change	-118.49%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$420.3K	$23.00K
YoY Change		1727.26%
Cash From Investing Activities	-$51.81K	$333.2K	$23.00K
YoY Change	-81.51%	1348.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-725.3K	$681.3K	-274.1K
YoY Change	-231.87%	-348.52%
NET CHANGE
Cash From Operating Activities	328.6K	-$931.5K	-1.001M
Cash From Investing Activities	-51.81K	$333.2K	23.00K
Cash From Financing Activities	-725.3K	$681.3K	-274.1K
Net Change In Cash	-448.5K	$82.92K	-1.252M
YoY Change	-50.63%	-106.62%
FREE CASH FLOW
Cash From Operating Activities	$328.6K	-$931.5K	-$1.001M
Capital Expenditures	$51.81K	$87.07K
Free Cash Flow	$276.7K	-$1.019M
YoY Change	-130.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2023Q1	MEDS	Increase Decrease In Undeposited Customer Funds IncreaseDecreaseInUndepositedCustomerFunds		usd
CY2022Q1	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities		usd
CY2022Q1	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability		usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2022Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities		usd
CY2022Q1	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue		usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		usd
CY2023Q1	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	MEDS	Note Cancelled From Sosrx Withdrawal NoteCancelledFromSosrxWithdrawal		usd
CY2022Q1	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets		usd
CY2023Q1	MEDS	Note Issued As Sosrx Contribution NoteIssuedAsSosrxContribution		usd
CY2023Q1	MEDS	Intangible Asset Contribution From Noncontrolling Interest IntangibleAssetContributionFromNoncontrollingInterest		usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39199
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
CY2023Q1	dei	City Area Code CityAreaCode	(800)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	261-0281
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
CY2023Q1	dei	Trading Symbol TradingSymbol	MEDS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10210878	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1194079	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1111156	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	707914	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	728601	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	126254	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	119582	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	357866	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	110945	usd
CY2022Q4	MEDS	Current Assets Of Discontinued Operations CurrentAssetsOfDiscontinuedOperations	22837	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2386113	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2093121	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62393	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65214	usd
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	537917	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	450845	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1002317	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051815	usd
CY2023Q1	us-gaap	Assets Assets	4037771	usd
CY2022Q4	us-gaap	Assets Assets	3710026	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	515766	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	682653	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	303225	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	290013	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	229165	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67517	usd
CY2023Q1	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	789286	usd
CY2022Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	108036	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	204064	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196872	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	508642	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	588533	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	166667	usd
CY2022Q4	MEDS	Current Liabilities Of Discontinued Operations CurrentLiabilitiesOfDiscontinuedOperations	46500	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2550148	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2146791	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	832483	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	887035	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	333333	usd
CY2023Q1	us-gaap	Liabilities Liabilities	3382631	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3367159	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10210878	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10210878	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9393708	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9393708	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	100	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	99	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20560499	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20482573	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19905459	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19719536	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	655140	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	763136	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-420269	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	655140	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4037771	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3710026	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2247750	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3240272	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	690670	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1904569	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1557080	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1335703	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	905901	usd
CY2022Q1	us-gaap	Salaries And Wages SalariesAndWages	1069958	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	139661	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	101009	usd
CY2023Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	248217	usd
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	236221	usd
CY2023Q1	MEDS	Technology Expense TechnologyExpense	233286	usd
CY2022Q1	MEDS	Technology Expense TechnologyExpense	245785	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	377421	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	651302	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1904486	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2304275	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-347406	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-968572	usd
CY2023Q1	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	79891	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4198	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4100	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	62392	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1364	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21697	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2736	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-325709	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-965836	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-352244	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-677953	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-960147	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5689	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.12
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10060735	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8178124	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63486	usd
CY2023Q1	MEDS	Stock Issued During Period Value Disposition Of Assets Related Party StockIssuedDuringPeriodValueDispositionOfAssetsRelatedParty	912299	usd
CY2023Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	7	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14434	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-677953	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	655140	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	17500	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	32083	usd
CY2022Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	32783	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-965836	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2887578	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2887578	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-677953	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-965836	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2821	usd
CY2022Q1	us-gaap	Depreciation Depreciation	3972	usd
CY2023Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	14434	usd
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	32783	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	63486	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	32083	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-32074	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1317	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1900	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	49498	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	54328	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	149229	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52761	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	63237	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22866	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	172857	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6672	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	217671	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47359	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-50322	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-166887	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	431467	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-210844	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	74501	usd
CY2022Q1	MEDS	Increase Decrease In Undeposited Customer Funds IncreaseDecreaseInUndepositedCustomerFunds	11166	usd
CY2023Q1	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	161648	usd
CY2023Q1	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-79891	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	996	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-899898	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1002381	usd
CY2023Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-31633	usd
CY2022Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1610	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-931531	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1000771	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware	87072	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-87072	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	23000	usd
CY2023Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	420269	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	333197	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	143750	usd
CY2023Q1	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
CY2022Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	275000	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	681257	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	875	usd
CY2022Q1	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-275000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	681257	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-274125	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82923	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1251896	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1111156	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1194079	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1870682	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	62392	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1364	usd
CY2023Q1	MEDS	Insurance Premium Financed InsurancePremiumFinanced	224055	usd
CY2022Q1	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
CY2023Q1	MEDS	Note Cancelled From Sosrx Withdrawal NoteCancelledFromSosrxWithdrawal	500000	usd
CY2023Q1	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets	492030	usd
CY2022Q1	MEDS	Note Issued As Sosrx Contribution NoteIssuedAsSosrxContribution	500000	usd
CY2022Q1	MEDS	Intangible Asset Contribution From Noncontrolling Interest IntangibleAssetContributionFromNoncontrollingInterest	792500	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Real Estate Discontinued Operations GainLossOnDispositionOfRealEstateDiscontinuedOperations	-352244	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	32074	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1317	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2689969	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-325709	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-965836	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-352244	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-677953	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-960147	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10060735	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8178124	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.12
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19900000	usd
CY2023Q1	MEDS	Working Capital WorkingCapital	164035	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1200000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2689969	shares
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.50
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P4Y8M19D
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	6731	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	-0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2689969	shares
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	1.49
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding	P4Y5M23D
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	7943	usd
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber	2689969	shares
CY2023Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	1.49
CY2023Q1	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P4Y5M23D
CY2023Q1	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1	7943	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14434	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	32783	usd
CY2023Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zjcE7UWCNMf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_82F_zeIM95PNPoX3">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Studebaker Defense Group, LLC</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $<span id="xdx_908_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zq2HX7eID5D8" title="Down payment">500,000</span> and Studebaker would deliver <span id="xdx_90D_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zVAwTvqgWaJb" title="Number of nitrile gloves delivered">180,000</span> boxes of nitrile gloves by August 14, 2020. Integra wired the $<span id="xdx_90A_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zgCFEXTAfVl" title="Loss contingency, damages sought, value">500,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $<span id="xdx_906_ecustom--LossOnInventoryInvestment_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zVeS4ni8Yna4" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $<span id="xdx_909_ecustom--DownPayment_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zOSc0qCMPTl6" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_905_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zNhuOP7wdre9" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. Integra wired the $<span id="xdx_902_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zMy6Mf2Jltd6" title="Loss contingency damages sought value">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zsfUss0gd1k8" title="Loss contingency damages sought value">581,250</span> and Crecom acknowledged that Integra was entitled to a refund. As of February 2021, Crecom had not returned any funds and Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by Integra was stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for Integra. At June 30, 2021, the $<span id="xdx_90F_ecustom--LossOnInventoryInvestment_c20210101__20210630__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zWh6JbvfBhFi" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GSG PPE, LLC</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, Integra filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and Integra executed a valid initial contract setting the terms of a business transaction. GSG failed to pay Integra approximately 75% of the amount owed to Integra. GSG acknowledged it owed the money and executed a promissory note in favor of Integra in the amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930_zpPByS2MZXod" title="Principal amount">630,000</span> which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_907_ecustom--AttorneyFees_c20230101__20230331_z6qNXdxaJZg3" title="Attorney fees">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed Integra $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__srt--TitleOfIndividualAxis__custom--WaxmanMember_z01t6vceI2Xh" title="Principal amount">630,000</span>. On September 30, 2021, the $<span id="xdx_902_eus-gaap--ProvisionForDoubtfulAccounts_c20210928__20210930_zHNWf4XEG9L" title="Bad debt expenses">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_90F_eus-gaap--LegalFees_c20220601__20220630_zKxLoguapdR4" title="Attorney fees">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received additional monthly installment payments as part of the agreement through January 2023. As of March 31, 2023, and through the date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jain, et al., v. Memantine, et al.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $<span id="xdx_90E_eus-gaap--LossContingencyDamagesPaidValue_c20210501__20210514_ze5Lt02pzoHf" title="Compensatory amount value">425,000</span> in compensatory damages, treble damages, punitive damages, and fees and costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and the Company was reached and signed. This settlement involved no admission of liability and a full and complete release of all actions after a lump-sum payment of $<span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20220201__20220228_zR3UNzis9ws" title="Settlement payment amount">225,000</span> was made. Because the complaint purports to be a derivative action, court approval was required, which approval was received on March 14, 2022. As a result of the settlement, the Plaintiff’s dismissed their lawsuit with prejudice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
CY2023Q1	MEDS	Attorney Fees AttorneyFees	630000	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	630000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	743000	usd
CY2021Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	425000	usd
CY2022Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	225000	usd
CY2023Q1	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
CY2023Q1	MEDS	Operating Lease Liabilities OperatingLeaseLiabilities	15000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	295884	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	304761	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	313903	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	254914	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	91373	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1260835	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	237868	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1022967	usd
CY2023Q1	MEDS	Lease Obligation Current LeaseObligationCurrent	202621	usd
CY2023Q1	MEDS	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	820346	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	13580	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	49498	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	54328	usd
CY2023Q1	MEDS	Amortization Of Lease Liability AmortizationOfLeaseLiability	47360	usd
CY2022Q1	MEDS	Amortization Of Lease Liability AmortizationOfLeaseLiability	50322	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2247750	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1557080	usd
CY2023Q1	us-gaap	Assets Assets	4037771	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-677953	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	690670	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3240272	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1335703	usd
CY2022Q1	us-gaap	Assets Assets	5840211	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-965836	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1904569	usd
CY2022Q3	MEDS	Minimum Stockholders Equity Requirement MinimumStockholdersEquityRequirement	2500000	usd
CY2023Q1	MEDS	Higher Limit Underwritten Public Offering HigherLimitUnderwrittenPublicOffering	15000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-017524-index-headers.html	Edgar Link	pending
0001493152-23-017524-index.html	Edgar Link	pending
0001493152-23-017524.txt	Edgar Link	pending
0001493152-23-017524-xbrl.zip	Edgar Link	pending
ex10-10.htm	Edgar Link	pending
ex10-10_001.jpg	Edgar Link	pending
ex10-10_002.jpg	Edgar Link	pending
ex10-10_003.jpg	Edgar Link	pending
ex10-10_004.jpg	Edgar Link	pending
ex10-10_005.jpg	Edgar Link	pending
ex10-10_006.jpg	Edgar Link	pending
ex10-10_007.jpg	Edgar Link	pending
ex10-10_008.jpg	Edgar Link	pending
ex10-10_009.jpg	Edgar Link	pending
ex10-10_010.jpg	Edgar Link	pending
ex10-10_011.jpg	Edgar Link	pending
ex10-10_012.jpg	Edgar Link	pending
ex10-10_013.jpg	Edgar Link	pending
ex10-10_014.jpg	Edgar Link	pending
ex10-10_015.jpg	Edgar Link	pending
ex10-10_016.jpg	Edgar Link	pending
ex10-10_017.jpg	Edgar Link	pending
ex10-10_018.jpg	Edgar Link	pending
ex10-10_019.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
image_001.jpg	Edgar Link	pending
logo_001.jpg	Edgar Link	pending
meds-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
meds-20230331_cal.xml	Edgar Link	unprocessable
meds-20230331_def.xml	Edgar Link	unprocessable
meds-20230331_pre.xml	Edgar Link	unprocessable
meds-20230331_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2023 Q2 Form 10-Q Financial Statement

#000149315223017524 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2023 Q2 Form 10-Q Financial Statement

#000149315223017524 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx